Patents by Inventor David Frank Savage

David Frank Savage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240029828
    Abstract: To reduce the total amount of linear sequence (DNA, RNA or other medium) required to encode a set of genetic elements, the present disclosure describes a computational method for compressing genetic information by finding one or more sequences that each mutually encode multiple genetic elements in the same stretch of sequence (a “co-encoding”). The computational method encodes each of the genetic elements in respective directed acyclic graphs (DAGs) or finite automatons (FAs), then encodes overlapping sequences between the DAGs or FAs in a second DAG or FA. Additional DAGs or FAs may be encoded for overlapping sequences that result from shifting the reading frame of the genetic elements relative to one another and switching the orientation of the elements.
    Type: Application
    Filed: December 9, 2021
    Publication date: January 25, 2024
    Inventors: David Frank Savage, John James Desmarais, Luke Mcdonald Oltrogge, Abraham Isser Flamholz
  • Patent number: 11180778
    Abstract: The present disclosure provides (i) RNA-guided polypeptides (e.g., circular permuted Cas9 proteins) in which the N-terminal end of an N-terminal fragment of a parent RNA-guided polypeptide (e.g., a parent Cas9 protein) is fused (e.g., via linker) to the C-terminal end of the C-terminal fragment (thereby generating new N- and C-termini), (ii) conditionally active RNA-guided polypeptides (e.g., conditionally active circular permuted Cas9 proteins), and (iiii) Cas9 fusion polypeptides that include an internal insertion of a heterologous polypeptide; as well as methods that employ the above polypeptides.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 23, 2021
    Assignee: The Regents of the University of California
    Inventors: David Frank Savage, Jennifer A. Doudna, Benjamin L. Oakes, Rayka Yokoo
  • Publication number: 20210269782
    Abstract: The present disclosure provides an RNA-guided effector polypeptide having a length that is less than Streptococcus pyogenes Cas9, and that retains the ability, when complexed with a guide RNA, to bind to a target nucleic acid. The present disclosure provides a fusion polypeptide comprising: i) an RNA-guided effector polypeptide of the present disclosure; and ii) a fusion partner. The present disclosure further provides nucleic acids encoding an RNA-guided effector polypeptide, or a fusion polypeptide, of the present disclosure. Methods of using an RNA-guided effector polypeptide, or a fusion polypeptide, of the present disclosure are also provided.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 2, 2021
    Inventors: Jennifer A. Doudna, David Frank Savage, Sean A. Higgins, Benjamin L. Oakes
  • Publication number: 20190233847
    Abstract: The present disclosure provides (i) RNA-guided polypeptides (e.g., circular permuted Cas9 proteins) in which the N-terminal end of an N-terminal fragment of a parent RNA-guided polypeptide (e.g., a parent Cas9 protein) is fused (e.g., via linker) to the C-terminal end of the C-terminal fragment (thereby generating new N- and C-termini), (ii) conditionally active RNA-guided polypeptides (e.g., conditionally active circular permuted Cas9 proteins), and (iiii) Cas9 fusion polypeptides that include an internal insertion of a heterologous polypeptide; as well as methods that employ the above polypeptides.
    Type: Application
    Filed: November 9, 2017
    Publication date: August 1, 2019
    Inventors: David Frank Savage, Jennifer A. Doudna, Benjamin L. Oakes, Rayka Yokoo